コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 role in the establishment and maintenance of latent tuberculosis.
2 osis compared with ongoing treatment or with latent tuberculosis.
3 treatment, and compared to individuals with latent tuberculosis.
4 response in PBMCs of persons with active or latent tuberculosis.
5 , and accurate prediction of reactivation of latent tuberculosis.
6 vaccine and the detection/treatment rate of latent tuberculosis.
7 nterfere with the detection and treatment of latent tuberculosis.
8 t infection that provides insight into human latent tuberculosis.
9 tween vaccination and detection/treatment of latent tuberculosis.
10 nhance eradication of persistent bacilli and latent tuberculosis.
11 e that resembles the dormant state seen with latent tuberculosis.
12 markers to distinguish BCG vaccination from latent tuberculosis.
13 nflammatory diseases, is the reactivation of latent tuberculosis.
14 emotherapeutic targets for active as well as latent tuberculosis.
15 potential for identifying vaccines targeting latent tuberculosis.
16 ntensive efforts to ensure full treatment of latent tuberculosis.
17 berculosis replication rates in persons with latent tuberculosis.
18 Isoniazid is an efficacious treatment for latent tuberculosis.
19 infection or reinfection of individuals with latent tuberculosis.
20 in Phase III efficacy trials of treatment of latent tuberculosis.
21 of stable granuloma, hallmark structures of latent tuberculosis.
22 preventing reactivation in a murine model of latent tuberculosis.
23 ed the high impact of detecting and treating latent tuberculosis.
24 fection compromises CD8+ T-cell functions in latent tuberculosis.
25 obacteria that are thought to play a role in latent tuberculosis.
26 culosis than HIV-uninfected individuals with latent tuberculosis.
27 he ROC curve (AUC) 0.90 [95% CI 0.85-0.95]), latent tuberculosis (0.88 [0.84-0.92]), and other diseas
28 practices also had increases in diagnosis of latent tuberculosis (11/59 [19%] vs 5/68 [9%], OR 3.00,
30 pregnant and postpartum women for active and latent tuberculosis; (4) the management of active and la
32 rculosis and 47.2% (95% CI, 30.0%-61.4%) for latent tuberculosis, although there was significant stat
33 Although guidelines on the management of latent tuberculosis and active tuberculosis are availabl
37 2% of the US population is estimated to have latent tuberculosis and there are only 11,000 cases annu
38 n derivative-negative controls, persons with latent tuberculosis, and BCG-vaccinated individuals.
39 been a considerable barrier to understanding latent tuberculosis, and efforts to develop new therapie
41 imilar among healthy controls, patients with latent tuberculosis, and patients with active tuberculos
42 n immunodeficiency virus (HIV) infection and latent tuberculosis are at substantial risk for the deve
44 s unlikely that a country detects and treats latent tuberculosis at a high enough rate to justify the
45 viously described with isoniazid therapy for latent tuberculosis but resulted in a high completion ra
46 c population isoniazid is a safe therapy for latent tuberculosis, but its effectiveness is limited by
47 own a high yield of tuberculosis disease and latent tuberculosis, but the yield of such investigation
48 rted data on migrant screening for active or latent tuberculosis by any method before migration to a
51 cidence included substance or alcohol abuse, latent tuberculosis, diabetes mellitus, atypical mycobac
53 es identified in all migrant groups included latent tuberculosis, found in 43% of migrants, eosinophi
57 nce between commercially available tests for latent tuberculosis in a low-prevalence population, incl
59 , our results suggest that the prevalence of latent tuberculosis in China might be overestimated by s
62 QuantiFERON-TB Gold test (QFT-GT) to detect latent tuberculosis in newly hired health care workers w
63 n a dormant state and may be responsible for latent tuberculosis in one-third of the world's populati
66 berculosis; (4) the management of active and latent tuberculosis in pregnancy and the postpartum peri
69 ornell model is a historical murine model of latent tuberculosis, in which mice infected with M. tube
70 n DC had a similar prevalence as refugees of latent tuberculosis infection (39% vs 38%, respectively,
71 ling approach, we show that individuals with latent tuberculosis infection (Ltb) and active tuberculo
72 dence of tuberculosis among individuals with latent tuberculosis infection (LTBI group) and without l
74 e used to evaluate new interventions against latent tuberculosis infection (LTBI) and predict reactiv
83 release assays (IGRAs) for the diagnosis of latent tuberculosis infection (LTBI) in individuals with
84 ates of noncompletion of treatment (NCT) for latent tuberculosis infection (LTBI) in the PREVENT TB t
88 an association between cigarette smoking and latent tuberculosis infection (LTBI) is based on studies
95 ence of the association between diabetes and latent tuberculosis infection (LTBI) remains limited and
98 sease is the identification and treatment of latent tuberculosis infection (LTBI) to prevent progress
99 HCW acceptance and compliance with available latent tuberculosis infection (LTBI) treatment regimens
107 be implemented that identified persons with latent tuberculosis infection among jail inmates and pro
108 lack the specificity to distinguish between latent tuberculosis infection and active tuberculosis.
109 T for identification of individuals who have latent tuberculosis infection and could improve tubercul
112 1,128 children who were all investigated for latent tuberculosis infection by tuberculin skin test an
113 on mRNA biogenesis pathways are repressed in latent tuberculosis infection compared with cured diseas
115 demonstrate how effective therapy for early latent tuberculosis infection has to be to eliminate tub
116 elling underline the necessity of addressing latent tuberculosis infection if further progress is to
117 yrazinamide are recommended for treatment of latent tuberculosis infection in adults without HIV infe
118 r progress, scale-up of targeted testing for latent tuberculosis infection in at-risk populations, sc
119 ive as daily isoniazid for 9 months (9H) for latent tuberculosis infection in high-risk persons, but
122 more sensitive than the TST for diagnosis of latent tuberculosis infection in patients on hemodialysi
123 ntify the effectiveness of therapy for early latent tuberculosis infection in reducing the prevalence
124 ard 9-month INH regimen for the treatment of latent tuberculosis infection in solid-organ transplant
125 ostic accuracy of these tests in determining latent tuberculosis infection in the hemodialysis popula
126 -G, and TSPOT.TB with regards to determining latent tuberculosis infection in the hemodialysis popula
127 e to that of the presumed background rate of latent tuberculosis infection in the state of Alabama.
128 ce-weekly isoniazid and rifapentine to treat latent tuberculosis infection in the United States, and
129 An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin an
130 active tuberculosis through the treatment of latent tuberculosis infection is a major element of the
131 f rifapentine and isoniazid for treatment of latent tuberculosis infection is safe and effective for
132 ronchoalveolar lavage cells from donors with latent tuberculosis infection limited the growth of viru
135 ated with one of three standard regimens for latent tuberculosis infection or tumor necrosis factor (
139 munodeficiency virus-induced reactivation of latent tuberculosis infection results in an increased ex
142 indicate reactivation risk, and even shorter latent tuberculosis infection treatment regimens than cu
143 ious periods, and clinicians should consider latent tuberculosis infection treatment-tailored to the
144 y searched for and included studies in which latent tuberculosis infection was assessed in 2 groups:
148 ng antiretroviral therapy; participants with latent tuberculosis infection were eligible if they had
150 ng tuberculosis from other diseases and from latent tuberculosis infection were identified from genom
152 e detected in three healthy individuals with latent tuberculosis infection who also had strong anti-M
153 ately distinguished active tuberculosis from latent tuberculosis infection with an area under the cur
155 ations, a strategy of detecting and treating latent tuberculosis infection would lead to substantial
156 itis B, and 133 [51%] of 263 individuals for latent tuberculosis infection), mental health (eg, highe
157 cells and the ability to control infection (latent tuberculosis infection, 62%; posttuberculosis pat
158 r memory phenotype in active tuberculosis vs latent tuberculosis infection, accompanied by a reductio
160 of active tuberculosis, the reactivation of latent tuberculosis infection, and the induction of prot
161 persons with greatest need for treatment of latent tuberculosis infection, as new shorter and less t
163 cy, including: (1) preventing progression of latent tuberculosis infection, especially in women coinf
165 uberculosis for experimental chemotherapy of latent tuberculosis infection, mice were immunized with
167 recommendations about diagnostic testing for latent tuberculosis infection, pulmonary tuberculosis, a
168 Standard assessments of interaction between latent tuberculosis infection, the HIV serostatus of ind
169 ts with anergy and multiple risk factors for latent tuberculosis infection, the rate of development o
170 ity in subjects with active tuberculosis and latent tuberculosis infection, with and without human im
171 l growth associated with stress survival and latent tuberculosis infection, yet the activities and in
191 tests available to determine the presence of latent tuberculosis infection: the tuberculin skin test
193 is, and screening and preventive therapy for latent tuberculosis infections in individuals with diabe
194 on is thought to be involved in establishing latent tuberculosis infections in response to hypoxia an
195 ch may explain why isoniazid monotherapy for latent tuberculosis is a risk factor for the emergence o
196 ial to the etiology of Tuberculosis, because latent tuberculosis is estimated to affect one-third of
200 dations for treating persons having presumed latent tuberculosis (LTBI) after contact to infectious m
201 idance on the optimal screening strategy for latent tuberculosis (LTBI) in patients about to start an
202 led trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of d
204 ared gene expression in patients with either latent tuberculosis or other diseases versus patients wi
205 01), behcet's disease (p = 0.0001), presumed latent tuberculosis (p = 0.0001), presumed latent syphil
206 01), behcet's disease, (p = 0.0001) presumed latent tuberculosis (p = 0.001), presumed latent syphili
207 et's disease, presumed sarcoidosis, presumed latent tuberculosis, presumed latent syphilis, and contr
209 e infection with M. tuberculosis and contain latent tuberculosis, providing a rationale for the clini
210 ent used to aid diagnosis of both active and latent tuberculosis, purified protein derivative (PPD),
212 t of nonreplicating persistence, and thereby latent tuberculosis, resisted extensive attempts at crys
214 n test (TST) to IFN-gamma release assays for latent tuberculosis screening are reporting challenges w
215 e assay (QFT) is increasingly being used for latent tuberculosis screening in patients infected with
216 during latency, and experimental studies on latent tuberculosis suffer from a lack of appropriate an
220 eveloping improved regimens for treatment of latent tuberculosis (TB) infection include (1) developin
221 between August 1, 2010 and July 31, 2011 for latent tuberculosis (TB) infection screening with an IGR
225 ew IFN-gamma release assays for diagnosis of latent tuberculosis (TB), but also provided evidence tha
230 blished prior to the widespread treatment of latent tuberculosis to estimate the incidence of tubercu
231 tis B virus and hepatitis C virus status and latent tuberculosis], to assess the risk of adverse even
233 s chapter provides an overview of active and latent tuberculosis treatment in HIV-infected and -uninf
234 as new shorter and less toxic regimens make latent tuberculosis treatment in older adults more attra
237 al-therapy-naive, HIV-1-infected adults with latent tuberculosis, we identified ten individuals with
238 to persist is key for finding ways to limit latent tuberculosis, which affects one-third of the worl
239 ation of a robust immune response leading to latent tuberculosis, which is regarded as a spectrum rat
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。